• Explore /
  • Poster
  • / Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.

Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.

Abstract Poster

Authors

null

Melania Pintilie

Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Melania Pintilie , Raya Leibowitz-Amit , A. Douglas Laird , Dana T. Aftab , Raanan Berger , Kim N. Chi , Anthony M. Joshua

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 196)

DOI

10.1200/jco.2015.33.7_suppl.196

Abstract #

196

Poster Bd #

J6

Abstract Disclosures

Similar Posters

First Author: Gliceida Galarza Fortuna

First Author: Umang Swami

First Author: Neeraj Agarwal

First Author: Neeraj Agarwal